COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00046800
Recruitment Status : Completed
First Posted : October 4, 2002
Last Update Posted : October 20, 2011
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Condition or disease Intervention/treatment Phase
Ovarian Neoplasms Drug: OSI-211 (Liposomal Lurtotecan) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
Study Start Date : September 2002
Actual Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed relapsed ovarian cancer.
  • Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
  • One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
  • At least three weeks since prior chemotherapy and recovery from any related toxicities.
  • At least four weeks since prior radiotherapy and recovery from any related toxicities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00046800

Layout table for location information
United States, New York
NYU- Kaplan Comprehensive Cancer Center
New York, New York, United States, 10016
United States, Tennessee
The Sarah Cannon Cancer Center, Centennial Medical Center
Nashville, Tennessee, United States, 37203
United Kingdom
St Chad's Unit
Birmingham, United Kingdom, B18 7QH
Beatson Oncology Centre
Glasgow, United Kingdom, G11 6NT
Royal Surrey County Hospital
Guildford, Surrey, United Kingdom, GU2 7XX
Royal Marsden NHS Trust
London, United Kingdom, SW3 6JJ
Northern Centre for Cancer Research, Newcastle General Hospital
Newcastle-upon-Tyne, United Kingdom, NE4 6BE
Mount Vernon Hospital
Northwood, Middlesex, United Kingdom, HA6 2RN
CRC Department of Medical Oncology
Sutton Surrey, United Kingdom, SM2 5PT
Taunton & Somerset Hospital
Taunton, United Kingdom, TA1 5DA
Medical Oncology Unit, Torbay District General Hospital
Torquay, United Kingdom, TQ2 7AA
Sponsors and Collaborators
Astellas Pharma Inc
OSI Pharmaceuticals
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT00046800    
Other Study ID Numbers: 110-20
First Posted: October 4, 2002    Key Record Dates
Last Update Posted: October 20, 2011
Last Verified: October 2011
Keywords provided by Astellas Pharma Inc:
Ovarian Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents